Department of Nuclear Medicine and Endocrine Oncology, Centre de Référence Tumeurs Réfractaires de la Thyroïde, Institut Gustave Roussy and University Paris-Sud XI, Villejuif, France.
Clin Oncol (R Coll Radiol). 2010 Aug;22(6):448-55. doi: 10.1016/j.clon.2010.04.008.
The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.
最近分子靶向治疗的出现，导致人们重新考虑对放射性碘治疗耐药的分化型甲状腺癌远处转移患者和转移性甲状腺髓样癌患者的治疗策略。对于疾病进展的患者，应提供激酶抑制剂治疗，最好在前瞻性试验的背景下。
